Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
📍 How it ended
Revolution Medicines presented Phase 1/2 clinical data for Zoldonrasib combination regimens for patients with RAS G12D metastatic pancreatic cancer at the ESMO Gastrointestinal Cancers Congress 2026. The company shared promising data regarding the KRAS drug combination.
Epilogue added 87d ago, after coverage quieted.
Coverage (5)
-
-
-
-
-
Revolution Medicines shares promising data around KRAS drug combination Endpoints News · 92d ago broke it first
What happened
- Velocity & Diffusion: Coverage escalated across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Revolution Medicines presented Phase 1/2 clinical data at the ESMO Gastrointestinal Cancers Congress 2026. The results focus on Zoldonrasib combination regimens, specifically Zoldonrasib plus Daraxonrasib, for patients with RAS G12D metastatic pancreatic cancer in 2nd and 3rd line settings.
Coverage from Endpoints News, Yahoo Finance, and Oncodaily highlights the promising nature of the data. Medscape describes the findings as practice-changing for GI oncology, while WSAW notes the experimental drug provides additional time and hope for patients.
Future developments center on the application of these combination regimens within gastrointestinal oncology and the progression of the experimental drug's clinical timeline.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 90d ago.
Questions people are asking
What specific cancer is being targeted?
The data focuses on patients with RAS G12D metastatic pancreatic cancer.
Which drugs are being used in the combination?
The combination involves Zoldonrasib and Daraxonrasib.
Where was this data presented?
The data was presented at the ESMO Gastrointestinal Cancers Congress 2026.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
People, places & organizations
Topics
Related trends
Chris Affleck, Mother of Oscar Winners Ben and Casey Affleck, Dies at 83
15 news sources are covering this Entertainment story right now — Newsylist is tracking how fast it spreads.
Pancreatic cancer vaccine shows promise in first human trial, preventing disease in high-risk patients
A first-in-human clinical trial for a mutant KRAS vaccine shows promise in preventing pancreatic cancer among high-risk patients.
Johns Hopkins surgeon highlights AI breakthrough that could spot pancreatic cancer before doctors
Healthcare leaders are balancing the integration of advanced AI diagnostic tools with the necessity of maintaining human-centric patient care.
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood gene test has demonstrated the ability to detect 90% of early-stage pancreatic cancers, a disease with a 13% survival rate.
A Vaccine to Prevent Pancreatic Cancer in High-risk Individuals Was Safe and Elicited Durable Immune Responses
10 news sources are covering this Health story right now — Newsylist is tracking how fast it spreads.
Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread
Ozempic and similar drugs being explored for potential cancer prevention benefits